Racing Toward the Next Hepatitis C Drug Approval

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

It appears that Johnson & Johnson (NYSE: JNJ  ) may have just leapfrogged over Gilead Sciences (NASDAQ: GILD  ) in the quest to bring the first next-generation hepatitis C drug to market. Johnson & Johnson said Monday that the Food and Drug Administration accepted its application for simeprevir and will give the drug a priority review.

You'll recall, Gilead submitted sofosbuvir for approval in the beginning of April. The FDA typically takes two months to make sure everything is in order before accepting the application for the standard 10-month review or a six-month priority review. The latest PDUFA renewal calls for the clock to start after the applications are accepted; it used to start when they were submitted.

It looks like Gilead is about a month behind Johnson & Johnson and could be five months behind if sofosbuvir gets a standard review, although that seems extremely unlikely. If simeprevir received the faster review, I'd expect the FDA to give it to sofosbuvir, too.

Getting to the market first is usually a big advantage, but I'm not sure if it'll actually help simeprevir to beat sofosbuvir by a month. Johnson & Johnson is asking for approval of the drug in combination with pegylated interferon and ribavirin. Pegylated interferon drugs -- Merck's (NYSE: MRK  ) PegIntron and Roche's Pegasys -- both have to be injected and cause unpleasant side effects.

Hepatitis C is a slow-developing disease, so there's no immediate rush to treat newly diagnosed patients as witnessed by the drop off in sales of Vertex Pharmaceuticals' (NASDAQ: VRTX  ) Incivek. In the first quarter, sales of the drug, which also has to be used in combination with pegylated interferon, fell 42% year over year. It's hard to see how simeprevir plus pegylated interferon would make inroads with doctors with all-oral hepatitis C combinations in the works.

Likewise, it's hard to see initial blustery sales for Gilead's sofosbuvir, which will be used in combination with pegylated interferon and ribavirin in genotype 1 patients, the most common hepatitis C genotype in the U.S.

For both drugs, the approvals are just a means to the end -- the end being part of an all-oral drug cocktail. Interestingly, sofosbuvir and simeprevir worked really well together without pegylated interferon in a small clinical trial.

Once they're both approved, doctors could prescribe a combination of the two drugs off label to patients, but given the aforementioned slowly developing nature of the disease, it seems unlikely that they'd go that route without extra data. Depending on how Gilead and Johnson & Johnson price their drugs, there could be a cost issue as well; insurers may be unwilling to reimburse for the two drugs off label.

Is bigger really better?
Involved in everything from baby powder to biotech, Johnson & Johnson's critics are convinced that the company is spread way too thin. If you want to know if J&J is nothing but a bloated corporate whale -- or a well-diversified giant that's perfect for your portfolio -- check out The Fool's new premium report outlining the Johnson & Johnson story in terms that any investor can understand. Claim your copy by clicking here now

Read/Post Comments (0) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2430185, ~/Articles/ArticleHandler.aspx, 9/26/2016 10:13:07 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 57 minutes ago Sponsored by:
DOW 18,094.83 -166.62 -0.91%
S&P 500 2,146.10 -18.59 -0.86%
NASD 5,257.49 -48.26 -0.91%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/26/2016 4:00 PM
GILD $80.62 Down -0.75 -0.92%
Gilead Sciences CAPS Rating: *****
JNJ $117.78 Down -1.03 -0.87%
Johnson and Johnso… CAPS Rating: *****
MRK $62.15 Down -0.81 -1.29%
Merck and Co. CAPS Rating: ****
VRTX $88.29 Down -2.34 -2.58%
Vertex Pharmaceuti… CAPS Rating: ****